Genprex Unveils Promising Data for Reqorsa® Gene Therapy at Major Cancer Conference

Genprex's Groundbreaking Findings on Reqorsa® Gene Therapy

Genprex, Inc., a pioneering clinical-stage gene therapy company, has recently made significant strides in the fight against cancer with the unveiling of positive preclinical findings for its Reqorsa® Gene Therapy. These findings were presented at the prestigious 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held from October 22 to 26 in Boston. This highlight reflects Genprex's commitment to transforming the treatment landscape for patients battling non-small cell lung cancer (NSCLC), particularly those with the ALK-EML4 positive variant.

In recently conducted research, it was revealed that Reqorsa (quaratusugene ozeplasmid) demonstrated remarkable efficacy in enhancing treatment outcomes when administered alongside Alectinib, a known ALK inhibitor. The combined therapy of Reqorsa and Alectinib led to an impressive increase in apoptosis among ALK+ NSCLC cells in mouse models, pointing to a potential new avenue for improving patient survival rates. According to Ryan Confer, President and CEO of Genprex, the data solidifies their oncology strategy aimed at reintroducing tumor suppressor genes to combat cancer cells effectively.